



Uly we claim

Claims

1. A compound of the formula



10 *TOZ41X/B* wherein A is the group
B or $-(CH_2)_5-$



8
9
B

15 2. The compound of claim 1, (2S,3S,5S,7Z,10Z)-5-[(S)-2-^{1,3}formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10^{1,3}hexadecadienoic acid lactone.


8
B

20 3. The compound of claim 1, (2S,3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic^{1,3} acid lactone.


13
N
X
A
P
35

25 4. A pharmaceutical composition comprising

a) about 5% to about 95% of a compound of formula



35 wherein A is the group
 or $-(CH_2)_5-$; and



Handwritten: 2
B
P3

b) 5% to 95% of a pharmaceutically acceptable carrier material, said composition being formulated in a unit dosage form.

5. The composition of claim 4 wherein said composition is formulated in an oral unit dosage form.

6. The composition of claim 5 wherein said oral unit dosage form is a tablet, dragee, capsule, solution, emulsion or suspension.

10
7. The composition of claim 4 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic^{1,3} acid lactone.


Handwritten: 8
B
P3

15
8. The composition of claim 4 wherein compound I is (2S, 3S, 5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic^{1,3} acid lactone.

Handwritten: 8
B
P3


9. A method of treating obesity in an afflicted mammal comprising administering to the mammal a compound of the formula

25 *Handwritten:* T0260X



30 *Handwritten:* T0261X
P3
P3

wherein A is the group
or $\overline{W}(\text{CH}_2)_5\overline{M}$



in an amount which is effective in treating obesity.


35
10. The method of claim 9 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic^{1,3} acid lactone.

Handwritten: 8
B
P3

8 9
B
11. The method of claim 9 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

12. The method of claim 9 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

13. A method of treating hyperlipaemia in an afflicted mammal comprising administering to the mammal a compound of the formula




TOZIKR
B
P
wherein A is the group or $-(CH_2)_5-$ in an amount which is effective in treating hyperlipaemia.

8 9
B
14. The method of claim 13 wherein compound I is (2S, 3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.

5 7
B
15. The method of claim 13 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

30 16. The method of claim 13 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

17. A method of preventing obesity in a mammal comprising administering to the mammal a compound of the formula



T0281y

10
B
B

wherein A is the group or $-(CH_2)_5-$

in an amount which is effective in preventing obesity.



by inhibiting Pomease lipase


18. The method of claim 17 wherein compound I is (2S, 15, 13S, 5S, 7Z, 10Z)-5-[(S)-2-Formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.

19. The method of claim 17 wherein compound I is (2S, 3S, 5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

20. The method of claim 17 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

END

21. A commercially-produced foodstuff comprising a compound of the formula



30

wherein A is the group or $-(CH_2)_5-$

admixed with a material suitable for consumption.

35 22. The foodstuff of claim 20 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone

23. The foodstuff of claim 20 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

5

10

15

20

25

30

35 -